This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 1, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Affymax, Inc. ("Affymax" or the "Company") (NASDAQ: AFFY).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) 2% of patients taking Affymax's kidney treatment drug Omontys were experiencing hypersensitivity reactions resulting in anaphylaxis, a serious and life-threatening allergic reaction; and (2) 0.02% of those taking Omontys experienced fatal anaphylaxis reactions.
February 23, 2013, Affymax announced that the U.S. Food and Drug Administration ("FDA") was requiring a total recall of the drug due to reports of anaphylaxis. According to the FDA, "serious and fatal" hypersensitivity reactions had been reported in some patients within 30 minutes of receiving their first doses of the drug by intravenous injection. On this news, the price of Affymax stock declined by more than 85%, closing at
$2.42 per share, down
$14.10 per share from the prior night's close.
Request more information now by clicking here: www.faruqilaw.com/AFFY. There is no cost or obligation to you.Take Action
If you invested in Affymax stock or options between
December 8, 2011 and
February 22, 2013 and would like to discuss your legal rights, visit
www.faruqilaw.com/AFFY. You can also contact us by calling
Richard Gonnello or
Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Affymax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (
www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP369 Lexington Avenue, 10th Floor
New York, NY 10017Attn:
Richard Gonnello, Esq.firstname.lastname@example.orgFrancis McConville, Esq.email@example.comTelephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP